Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

Summation

  • Market Gateway Accelerator for BioSciences and MedTech”, sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.
  • We will also introduce PidPort, our AI-powered cloud system designed to support digital pathology, at the upcoming “Philadelphia Alliance for Capital and Technology Conference”, the largest annual startup conference in Philadelphia, which will be held in November.
  • Com), a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that it has been selected for the “U.

Medmain Inc. (https://en.medmain.com), a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that it has been selected for the “U.S. Market Gateway Accelerator for BioSciences and MedTech”, an acceleration program sponsored by WorldUpstart, LLC. We will take advantage of this opportunity to move forward with our business development in the U.S.

The “U.S. Market Gateway Accelerator for BioSciences and MedTech”, sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market. The program receives applications from startups from all over the world, which must go through a rigorous evaluation process before being selected.

Through this program, the company will receive advice on business development in the U.S., ranging from FDA filings, marketing strategies for the U.S. healthcare market, intellectual property strategies, financing and business alliance strategies, and promotional support, among others.

We will also introduce PidPort, our AI-powered cloud system designed to support digital pathology, at the upcoming “Philadelphia Alliance for Capital and Technology Conference”, the largest annual startup conference in Philadelphia, which will be held in November.

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy